Name | Marbofloxacin |
Synonyms | CS-939 Marbofloxacin MARBOFLOXACIN Marbofloxacin Solution, 100ppm Marbofloxacin Solution, 1000ppm o-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo- 7h-pyrido(3,2,1-ij)(4,1,2)benzoxadiazine-6-carboxylicacid,2,3-dihydro-9-fluor 9-FLUORO-2,3-DIHYDRO-3-METHYL-10-(4-METHYL-PIPERAZINO)-7-OXO-7H-PYRIDO[1,2,3-IJ][1,2,4]BENZOXADIAZINE-6-CARBOXYLIC ACID 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-piperazino)-7-oxo-7h-pyrido[1,2,3-ij][1,2,4]benzoxadiazine-6-carboxylic acid 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,3,4]oxadiazino[6,5,4-ij]quinoline-6-carboxylic acid 9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[3,2,1-ij][4,1,2]benzoxadiazine-6-carboxylic acid |
CAS | 115550-35-1 |
EINECS | 640-416-5 |
InChI | InChI=1/C17H19FN4O4/c1-19-3-5-21(6-4-19)14-12(18)7-10-13-16(14)26-9-20(2)22(13)8-11(15(10)23)17(24)25/h7-8H,3-6,9H2,1-2H3,(H,24,25) |
InChIKey | BPFYOAJNDMUVBL-UHFFFAOYSA-N |
Molecular Formula | C17H19FN4O4 |
Molar Mass | 362.36 |
Density | 1.55±0.1 g/cm3(Predicted) |
Melting Point | 268-269°C (dec.) |
Boling Point | 571℃ |
Flash Point | >110°(230°F) |
Water Solubility | Soluble in DMSO at 2mg/ml. Soluble in water or ethanol at <1mg/ml |
Solubility | Soluble in DMSO 2 mg/ml, soluble in water or ethanol <1 mg/ml |
Vapor Presure | 7.45E-14mmHg at 25°C |
Appearance | Yellow or light yellow powder |
Color | Light Yellow |
Merck | 14,5750 |
pKa | 6.02±0.20(Predicted) |
Storage Condition | Inert atmosphere,2-8°C |
Refractive Index | 1.701 |
MDL | MFCD00864820 |
In vitro study | Marbofloxacin is a Fluoroquinolone antibacterial agent, specially used for veterinary use. Marbofloxacin acts on a broad spectrum of aerobic Gram-negative and some Gram-positive bacteria, as well as mycoplasmas, with high bactericidal activity. As a third-generation Fluoroquinolone, Marbofloxacin also primarily targets replication and transcriptase enzymes such as DNA helicase and topoisomerase IV, both of which are important for bacterial survival. Marbofloxacin significantly killed Leishmania promastigotes and intracellular non-mastigotes in a dose-dependent manner and was more effective than meglumine antimonate and sodium antimony gluconate. After Marbofloxacin treatment, macrophages acquire anti-infection ability and enhance anti-Leishmania activity through the NO synthase pathway. |
In vivo study | In Vivo, Marbofloxacin treated M. hyopneumoniae 116 wild-type strain and clonal re-isolated strain at therapeutic dose for 4 days, with mycoplasmacidal effect in logarithmic phase instead of lag phase. Marbofloxacin at therapeutic doses does not eliminate M. hyopneumoniae, and 87.5 to 100 percent of the pigs remain positive after testing and are not effective in reducing clinical symptoms. However, Marbofloxacin treatment appears to reduce lung injury. Treatment of Marbofloxacin at a dose of 6 mg/kg once daily for 7 days in tissue structures of pony infected with S. Aureus was not effective in eliminating S. Aureus infection from cryptic sites. |
Hazard Symbols | Xi - Irritant |
Risk Codes | R52/53 - Harmful to aquatic organisms, may cause long-term adverse effects in the aquatic environment. R36/37/38 - Irritating to eyes, respiratory system and skin. |
Safety Description | S61 - Avoid release to the environment. Refer to special instructions / safety data sheets. S36 - Wear suitable protective clothing. S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S60 - This material and its container must be disposed of as hazardous waste. |
WGK Germany | 2 |
RTECS | UU8815140 |
HS Code | 29349990 |